{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:11:10Z","timestamp":1785510670496,"version":"3.56.0"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.yrtph.2026.106133","type":"journal-article","created":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T17:30:52Z","timestamp":1781458252000},"page":"106133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Non-clinical toxicology of therapeutic vaccines: Regulatory considerations and species selection: A comprehensive review"],"prefix":"10.1016","volume":"171","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2848-2817","authenticated-orcid":false,"given":"S.","family":"Gould","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Londono-Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yrtph.2026.106133_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2022.105327","article-title":"FDA and industry collaboration: identifying opportunities to further reduce reliance on nonhuman primates for nonclinical safety evaluations","volume":"138","author":"Ackley","year":"2023","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"10","key":"10.1016\/j.yrtph.2026.106133_bib2","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.7326\/ANNALS-25-00997","article-title":"Aluminum-adsorbed vaccines and chronic diseases in childhood. A nationwide cohort study","volume":"178","author":"Andersson","year":"2025","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.yrtph.2026.106133_bib3","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2471\/BLT.07.040089","article-title":"Vaccination greatly reduces disease, disability, death and inequity worldwide","volume":"86","author":"Andre","year":"2008","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.yrtph.2026.106133_bib4","first-page":"2","article-title":"Development of COVID-19 therapies: nonclinical testing considerations Regulatory","volume":"13","author":"Baldrick","year":"2022","journal-title":"Toxicology and Pharmacology"},{"key":"10.1016\/j.yrtph.2026.106133_bib5","first-page":"28","volume":"vol. 42","author":"Benlaribi","year":"2022"},{"key":"10.1016\/j.yrtph.2026.106133_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.867015","article-title":"A comprehensive Atlas of immunological differences between humans, mice, and non-human Primates","volume":"13","author":"Bjornson-Hooper","year":"2022","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.yrtph.2026.106133_bib7","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2273699","article-title":"Preclinical support for tumor protein D52 as a cancer vaccine antigen","volume":"19","author":"Bright","year":"2023","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.yrtph.2026.106133_bib8","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41541-024-00893-1","article-title":"Myocarditis associated with COVID-19 vaccination","volume":"9","author":"Buoninfante","year":"2024","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.yrtph.2026.106133_bib9","article-title":"The cutter incident: how America's first polio vaccine led to the growing vaccine crisis","volume":"332","author":"Carapetis","year":"2006","journal-title":"B.M.J"},{"key":"10.1016\/j.yrtph.2026.106133_bib10","series-title":"United States of America Department of Health and Human Services COVID-19 Vaccine Safety Technical (Vast) Work Group Report","year":"2021"},{"key":"10.1016\/j.yrtph.2026.106133_bib11","doi-asserted-by":"crossref","first-page":"9470","DOI":"10.3390\/ijms23169470","article-title":"Vaccine for Diabetes\u2014Where do we stand?","volume":"23","author":"Chellappan","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yrtph.2026.106133_bib12","series-title":"ICH Considerations Oncolytic Viruses","year":"2008"},{"issue":"5","key":"10.1016\/j.yrtph.2026.106133_bib13","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cmi.2023.12.010","article-title":"Comparative safety analysis of mRNA and adenoviral vector COVID-19 vaccines: a nationwide cohort study using an emulated target trial approach","volume":"30","author":"Choi","year":"2024","journal-title":"Clin. Microbiol. Infection"},{"issue":"2","key":"10.1016\/j.yrtph.2026.106133_bib14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1089\/jir.2008.0004","article-title":"Comparison of rat and human responses to toll-like receptor 7 activation","volume":"29","author":"Clarke","year":"2009","journal-title":"J. Interferon Cytokine Res."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106133_bib15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4103\/0974-777X.77299","article-title":"Fundamentals of vaccine immunology","volume":"3","author":"Clem","year":"2011","journal-title":"J. Global Infect. Dis."},{"key":"10.1016\/j.yrtph.2026.106133_bib16","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1016\/j.vaccine.2016.04.060","article-title":"Unique safety issues associated with virus-vectored vaccines: potential for and theoretical consequences of recombination with wild type virus strains","volume":"34","author":"Condit","year":"2016","journal-title":"Vaccine"},{"issue":"Suppl. 2","key":"10.1016\/j.yrtph.2026.106133_bib17","article-title":"Vaccine safety issues at the turn of the 21st century","volume":"6","author":"Conklin","year":"2021","journal-title":"BMJ Glob. Health"},{"key":"10.1016\/j.yrtph.2026.106133_bib18","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12016-011-8294-7","article-title":"Molecular mimicry as a mechanism of autoimmune disease","volume":"42","author":"Cusick","year":"2012","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.yrtph.2026.106133_bib19","article-title":"Molecular mimicry: antigen sharing by parasite and host and its consequences","volume":"1","author":"Damian","year":"1964","journal-title":"Am. Nat."},{"issue":"Suppl. 2","key":"10.1016\/j.yrtph.2026.106133_bib20","first-page":"A1","article-title":"Phase I dose escalation study of stemvac, a multi-antigen, multi-epitope th1 selective Plasmid-based vaccine, targeting stem cell Associated proteins in patients with advanced Breast cancer","volume":"10","author":"Disis","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.yrtph.2026.106133_bib21","series-title":"Guideline on Data Requirements for Vaccine Platform Technology Master Files (vPTMF)","year":"2022"},{"key":"10.1016\/j.yrtph.2026.106133_bib22","series-title":"Signal Assessment Report on Myocarditis, Pericarditis with Tozinameran (COVID-19 Mrna Vaccine (Nucleoside Modified) \u2013 Comirnaty) EPITT No: 19712 Procedure No: EMEA\/H\/C\/005735\/SDA\/032.2","year":"2021"},{"key":"10.1016\/j.yrtph.2026.106133_bib23","series-title":"Guidance for Industry: Considerations for Developmental Toxicity Studies for Preventive and Therapeutic Vaccines for Infectious Disease Indications","year":"2006"},{"key":"10.1016\/j.yrtph.2026.106133_bib24","series-title":"Considerations for Plasmid DNA Vaccines for Infectious Disease Indications","year":"2007"},{"key":"10.1016\/j.yrtph.2026.106133_bib25","series-title":"Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines","year":"2011"},{"key":"10.1016\/j.yrtph.2026.106133_bib26","series-title":"Preclinical Assessment of Investigational Cellular and Gene Therapy Products","year":"2013"},{"key":"10.1016\/j.yrtph.2026.106133_bib27","series-title":"Design and Analysis of Shedding Studies for Virus or Bacteria-based Gene Therapy and Oncolytic Product","year":"2015"},{"key":"10.1016\/j.yrtph.2026.106133_bib28","article-title":"The primate major histocompatibility complex: a case Study of gene family evolution","author":"Fortier","year":"2025","journal-title":"bioRxiv: the preprint server for biology"},{"key":"10.1016\/j.yrtph.2026.106133_bib29","doi-asserted-by":"crossref","first-page":"977","DOI":"10.15585\/mmwr.mm7027e2","article-title":"Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the advisory Committee on Immunization Practices - United States","volume":"70","author":"Gargano","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.yrtph.2026.106133_bib30","series-title":"Chapter 2. Pathology of the Laboratory RabbitISBN :","isbn-type":"print","author":"Gould","year":"2025","ISBN":"https:\/\/id.crossref.org\/isbn\/9780128225288"},{"key":"10.1016\/j.yrtph.2026.106133_bib31","article-title":"Vaccine toxicology in the post-covid era","author":"Gould","year":"2026","journal-title":"Toxicology Sciences"},{"key":"10.1016\/j.yrtph.2026.106133_bib32","doi-asserted-by":"crossref","first-page":"5919","DOI":"10.1016\/j.vaccine.2023.08.040","article-title":"Report from an ICT 2022 workshop on toxicology for Covid19 vaccines: industry, regulatory and CRO perspectives","volume":"41","author":"Gould","year":"2023","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.yrtph.2026.106133_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0239780","article-title":"Cocaine vaccine dAd5GNE protects against moderate daily and high dose \u201cbinge\u201d cocaine use","volume":"15","author":"Havlicek","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.yrtph.2026.106133_bib34","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/iji.12490","article-title":"Comparative genetics of the major histocompatibility complex in humans and nonhuman primates","volume":"47","author":"Heijmans","year":"2020","journal-title":"Int. J. Immunogenet."},{"key":"10.1016\/j.yrtph.2026.106133_bib35","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2471\/BLT.10.079426","article-title":"Intradermal delivery of vaccines: potential benefits and current challenges","volume":"89","author":"Hickling","year":"2011","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.yrtph.2026.106133_bib36","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1038\/s41388-022-02222-z","article-title":"Safety and efficacy of prophylactic and therapeutic vaccine based on live-attenuated Listeria monocytogenes in hepatobiliary cancers","volume":"41","author":"Hochnadel","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.yrtph.2026.106133_bib37","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1186\/1471-2458-12-1052","article-title":"The efficacy and safety of a nicotine conjugate vaccine (NicVAX\u00ae) or placebo co-administered with varenicline (Champix\u00ae) for smoking cessation: study protocol of a phase IIb, double blind, randomized, placebo-controlled trial","volume":"12","author":"Hoogsteder","year":"2021","journal-title":"BMC Public Health"},{"issue":"11","key":"10.1016\/j.yrtph.2026.106133_bib38","doi-asserted-by":"crossref","first-page":"972","DOI":"10.3109\/00498254.2011.598582","article-title":"Interspecies scaling and prediction of human clearance: comparison of small- and macro-molecule drugs","volume":"41","author":"Huh","year":"2011","journal-title":"Xenobiotica"},{"issue":"4","key":"10.1016\/j.yrtph.2026.106133_bib39","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1101\/gr.1987704","article-title":"The genomic sequence and comparative analysis of the rat major histocompatibility complex","volume":"14","author":"Hurt","year":"2004","journal-title":"Genome Res."},{"key":"10.1016\/j.yrtph.2026.106133_bib40","unstructured":"ICH M3 (R2) Non-Clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals - Scientific Guideline."},{"key":"10.1016\/j.yrtph.2026.106133_bib41","unstructured":"ICHS6: ICH S6 (R1) Preclinical Safety Evaluation of biotechnology-derived Pharmaceuticals - Scientific Guideline."},{"issue":"Part 3","key":"10.1016\/j.yrtph.2026.106133_bib42","article-title":"Immunoinformatics-driven multi-epitope peptide vaccine design targeting hepatitis C virus E1\/E2 envelope protein","volume":"1349","author":"Iyyanar","year":"2026","journal-title":"J. Mol. Struct."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106133_bib43","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13567-020-00806-9","article-title":"Characterization of humoral and cell-mediated immunity in rabbits orally infected with Encephalitozoon cuniculi","volume":"51","author":"Jeklova","year":"2020","journal-title":"Veterinary Research"},{"key":"10.1016\/j.yrtph.2026.106133_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.115140","article-title":"Vaccines for immune tolerance against autoimmune disease","volume":"203","author":"Kim","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.yrtph.2026.106133_bib45","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4266\/acc.2017.00045","article-title":"Acute fulminant myocarditis following influenza vaccination requiring extracorporeal membrane oxygenation","volume":"34","author":"Kim","year":"2019","journal-title":"Acute and Critical Care"},{"key":"10.1016\/j.yrtph.2026.106133_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.iotech.2022.100267","article-title":"155P BNT113 + pembrolizumab as first-line treatment in patients with unresectable recurrent\/metastatic HNSCC: preliminary safety data from AHEAD-MERIT","volume":"16","author":"Klinghammer","year":"2022","journal-title":"Immuno-Oncology and Technology"},{"issue":"12","key":"10.1016\/j.yrtph.2026.106133_bib47","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.vaccine.2018.02.030","article-title":"Myocarditis and pericarditis are rare following live viral vaccinations in adults","volume":"36","author":"Kuntz","year":"2018","journal-title":"Vaccine"},{"issue":"43","key":"10.1016\/j.yrtph.2026.106133_bib48","doi-asserted-by":"crossref","first-page":"5593","DOI":"10.1016\/j.vaccine.2014.07.104","article-title":"TLR7\/8 agonists activate a mild immune response in rabbits through TLR8 but not TLR7","volume":"32","author":"Lai","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.yrtph.2026.106133_bib49","volume":"76","year":"2022","journal-title":"The 3Rs of Animal Research"},{"key":"10.1016\/j.yrtph.2026.106133_bib50","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13046-019-1154-7","article-title":"Cancer DNA vaccines: current preclinical and clinical developments and future perspectives","volume":"38","author":"Lopes","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.yrtph.2026.106133_bib51","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S1470-2045(22)00372-2","article-title":"Clinical advances and ongoing trials of mRNA vaccines for cancer treatment","author":"Lorentzen","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.yrtph.2026.106133_bib52","first-page":"92","article-title":"First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response","volume":"178","author":"MacGregor","year":"1998","journal-title":"Clinical Trial J. Infect. Dis."},{"issue":"10","key":"10.1016\/j.yrtph.2026.106133_bib53","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1001\/archgenpsychiatry.2009.128","article-title":"Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial","volume":"66","author":"Martell","year":"2009","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1","key":"10.1016\/j.yrtph.2026.106133_bib54","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.yrtph.2014.06.029","article-title":"Considerations for non-clinical safety studies of therapeutic peptide vaccines","volume":"70","author":"Matsumoto","year":"2014","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106133_bib55","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1146\/annurev.iy.12.040194.005015","article-title":"Tolerance, danger, and the extended family","volume":"12","author":"Matzinger","year":"1994","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.yrtph.2026.106133_bib56","first-page":"372","article-title":"Oncogenic human papillomaviruses","volume":"19","author":"McBride","year":"2017","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"issue":"11","key":"10.1016\/j.yrtph.2026.106133_bib57","first-page":"1012","article-title":"HLA DQB1\u22170602 is associated with cataplexy in 509 narcoleptic patients","volume":"20","author":"Mignot","year":"1997","journal-title":"Sleep"},{"key":"10.1016\/j.yrtph.2026.106133_bib58","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/s41423-022-00897-8","article-title":"Virus-like particle vaccinology, from bench to bedside","volume":"19","author":"Mohsen","year":"2022","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.yrtph.2026.106133_bib59","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12860-020-00279-w","article-title":"Polyvalent therapeutic vaccine for type 2 diabetes mellitus: immunoinformatics approach to study co-stimulation of cytokines and GLUT1 receptors","volume":"21","author":"Muhammad","year":"2020","journal-title":"BMC Molecular and Cell Biology"},{"key":"10.1016\/j.yrtph.2026.106133_bib60","series-title":"B and T Lymphocytes in Rabbits Change According to the Sex and Throughout the Year","author":"Nied\u017awiedzka-Rystwej","year":"2020"},{"key":"10.1016\/j.yrtph.2026.106133_bib61","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00427-003-0301-4","article-title":"Hypothesis Paper published: 18 February 2003 Patterns of gene expression: homology or homocracy?","volume":"213","author":"Nielsen","year":"2003","journal-title":"Dev. Gene. Evol."},{"key":"10.1016\/j.yrtph.2026.106133_bib62","series-title":"Phylogeny. Encyclopedia of Biodiversity","first-page":"5237","author":"Nixon","year":"2001"},{"key":"10.1016\/j.yrtph.2026.106133_bib63","first-page":"2","article-title":"An introduction to sequence similarity (\"homology\") searching","author":"Pearson","year":"2013","journal-title":"Curr. Protoc. Bioinform."},{"issue":"12","key":"10.1016\/j.yrtph.2026.106133_bib64","article-title":"A phase II Study evaluating the interest to combine UCPVax, a telomerase CD4 TH1-Inducer cancer vaccine, and atezolizumab for the treatment of HPV positive cancers: vol ATIL Study","volume":"19","author":"Peixoto","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.yrtph.2026.106133_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.hlc.2021.07.011","article-title":"Myocarditis, pericarditis and cardiomyopathy after COVID-19 vaccination","author":"Pepe","year":"2021","journal-title":"Heart Lung Circ."},{"issue":"34","key":"10.1016\/j.yrtph.2026.106133_bib66","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1400472111","article-title":"History of vaccination","volume":"111","author":"Plotkin","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"8","key":"10.1016\/j.yrtph.2026.106133_bib67","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.vaccine.2020.01.024","article-title":"The science of vaccine safety: summary of meeting at Wellcome Trust","volume":"38","author":"Plotkin","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.yrtph.2026.106133_bib68","article-title":"Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials","volume":"8","author":"Pol","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.yrtph.2026.106133_bib69","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging concepts in the science of vaccine adjuvants","volume":"20","author":"Pulendran","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.yrtph.2026.106133_bib70","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.tig.2020.01.008","article-title":"Advances in the evolutionary understanding of MHC polymorphism","volume":"36","author":"Radwan","year":"2020","journal-title":"Trends Genet.: TIG (Trends Genet.)"},{"issue":"issue 1","key":"10.1016\/j.yrtph.2026.106133_bib71","article-title":"Are repeat-dose toxicity studies informative for safety assessment of Vaccine Candidates? A Survey of vaccine developers","volume":"44","author":"Rohdes","year":"2024","journal-title":"Int. J. Toxicol."},{"key":"10.1016\/j.yrtph.2026.106133_bib72","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jaut.2018.10.012","article-title":"Journal of Autoimmunity Molecular mimicry and autoimmunity","volume":"95","author":"Rojas","year":"2018","journal-title":"J. Autoimmun."},{"issue":"4","key":"10.1016\/j.yrtph.2026.106133_bib73","first-page":"581","article-title":"T- and B-cell surface markers on rabbit lymphocytes","volume":"32","author":"Sabolovi\u0107","year":"1977","journal-title":"Immunology"},{"key":"10.1016\/j.yrtph.2026.106133_bib74","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1586\/1744666X.2013.824686","article-title":"Did the influenza A (H1N1). 2009. monovalent inactivated vaccines increase the risk for Guillain-Barre syndrome?","volume":"9","author":"Salmon","year":"2013","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"4","key":"10.1016\/j.yrtph.2026.106133_bib75","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1084\/jem.178.4.1337","article-title":"Selection of rabbit CD4- CD8- T cell receptor-gamma\/delta cells by in vitro transformation with human T lymphotropic virus-I","volume":"178","author":"Sawasdikosol","year":"1993","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.yrtph.2026.106133_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2023.105438","article-title":"Evaluation of non-clinical toxicity studies of COVID-19 vaccines","volume":"142","author":"Schilder","year":"2023","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106133_bib77","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242316591","article-title":"Personalized cancer vaccines Go viral: viral vectors in the era of personalized immunotherapy of cancer","volume":"24","author":"Secli","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yrtph.2026.106133_bib78","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41541-025-01118-9","article-title":"Multi-disciplinary approaches paving the way for clinically effective peptide vaccines for cancer","volume":"10","author":"Shah","year":"2025","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.yrtph.2026.106133_bib79","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/imm.12624","article-title":"Comparative genomics of the human, macaque and mouse major histocompatibility complex","volume":"150","author":"Shiina","year":"2016","journal-title":"Immunology"},{"key":"10.1016\/j.yrtph.2026.106133_bib80","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/15569527.2016.1178277","article-title":"The importance of minipigs in dermal safety assessment: an overview","volume":"36","author":"Stricker-Krongrad","year":"2017","journal-title":"Cutan. Ocul. Toxicol."},{"key":"10.1016\/j.yrtph.2026.106133_bib81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.dmpk.2021.100424","article-title":"Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs","volume":"41","author":"Suzuki","year":"2021","journal-title":"Drug Metabol. Pharmacokinet."},{"key":"10.1016\/j.yrtph.2026.106133_bib82","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.cell.2010.01.022","article-title":"Pattern recognition receptors and inflammation","volume":"140","author":"Takeuchi","year":"2010","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.yrtph.2026.106133_bib83","first-page":"524","article-title":"Past, present, and future of viral vector vaccine platforms","volume":"13","author":"Tang","year":"2025","journal-title":"A Comprehensive Review"},{"key":"10.1016\/j.yrtph.2026.106133_bib84","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.vaccine.2015.01.073","article-title":"The safety of vaccine adjuvants: focus on autoimmunity","volume":"33","author":"Van de Laan","year":"2015","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.yrtph.2026.106133_bib85","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/01926233241311259","article-title":"Applications of cell-based protein array technology to preclinical safety assessment of biological products","volume":"53","author":"Vicart","year":"2025","journal-title":"Toxicol. Pathol."},{"issue":"4","key":"10.1016\/j.yrtph.2026.106133_bib86","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/joim.12395","article-title":"Human autoimmune diseases: a comprehensive update Review","volume":"278","author":"Wang","year":"2015","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.yrtph.2026.106133_bib87","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41392-023-01408-5","article-title":"Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.yrtph.2026.106133_bib88","series-title":"Nonclinical Evaluation of Vaccine Adjuvants and Adjuvanted Vaccines","year":"2013"},{"key":"10.1016\/j.yrtph.2026.106133_bib89","series-title":"Valuation of the Quality, Safety and Efficacy of Messenger RNA Vaccines for the Prevention of Infectious Diseases: Regulatory Consideration","year":"2021"},{"key":"10.1016\/j.yrtph.2026.106133_bib90","first-page":"323","article-title":"Strategies for the nonclinical safety assessment of vaccines","volume":"2","author":"Wolf","year":"2012","journal-title":"Novel Immune Potentiators and Delivery Technologies for Next Generation Vaccines"},{"key":"10.1016\/j.yrtph.2026.106133_bib91","first-page":"200","volume":"vol 927","year":"2005"},{"key":"10.1016\/j.yrtph.2026.106133_bib92","series-title":"State of the World's Vaccines and Immunization","year":"2009"},{"issue":"9396","key":"10.1016\/j.yrtph.2026.106133_bib93","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/S0140-6736(03)14802-7","article-title":"Vaccination and autoimmune disease: what is the evidence?","volume":"362","author":"Wraith","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.yrtph.2026.106133_bib94","article-title":"Review of adverse events associated with COVID-19 vaccines, highlighting their frequencies and reported cases","volume":"18","author":"Yaamika","year":"2023","journal-title":"J. Taibah Univ. Med. Sci."},{"key":"10.1016\/j.yrtph.2026.106133_bib95","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.virusres.2016.12.002","article-title":"The current state of therapeutic and T cell-based vaccines against human papillomaviruses","volume":"231","author":"Yang","year":"2017","journal-title":"Virus Res."},{"issue":"6","key":"10.1016\/j.yrtph.2026.106133_bib96","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1016\/j.ymthe.2025.03.034","article-title":"Clinical development of therapeutic mRNA applications mRNA vaccine","volume":"33","author":"Zak","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.yrtph.2026.106133_bib97","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","article-title":"Vaccine adjuvants: mechanisms and platform","volume":"8","author":"Zhao","year":"2023","journal-title":"Review Article Signal Transduction and Targeted Therapy"},{"issue":"Suppl. 2","key":"10.1016\/j.yrtph.2026.106133_bib98","first-page":"1","article-title":"Evolving pharmacovigilance requirements with novel vaccines and vaccine components","volume":"6","author":"Zuber","year":"2021","journal-title":"BMJ Glob. Health"}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230026001066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230026001066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:34:21Z","timestamp":1785508461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230026001066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":98,"alternative-id":["S0273230026001066"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2026.106133","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-clinical toxicology of therapeutic vaccines: Regulatory considerations and species selection: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2026.106133","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106133"}}